Please assess the completion status of the following clinical trial:

Trial Title: Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed chinese colorectal cancer patients and imaging detection confirmed liver metastasis~2. previously no treatment for liver metastasis or Primary tumor had been removed and last additional chemotherapy over one year~3. Age of≥18 and ≤75~4. Adequate organ functions, as determined by normal bone marrow function (absolute neutrophil count2 x 109/L, platelets 100 x 109/L, White blood cells 4 x 109/L), liver function (serum bilirubin ≤ 2.5 x ULN, serum transaminases ≤2. 5x ULN)~5. ECOG≤1~6. Life Expectancy\>6months~7. Signed written informed consent~8. Expected adequacy of follow-up~Exclusion Criteria:~1. Lesion is too small to assess by imaging~2. Extrahepatic metastases~3. Any anticancer chemotherapy in development within 4 weeks prior to study entry~4. Concurrent uncontrolled illness such as infection~5. Be allergic to medicines in the study~6. Pregnant or nursing patients~7. Fertile women (\< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.~8. Not willing or incapable to comply with all study visits and assessments~9. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that puts the patient at high risk for treatment-related complications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Raltitrexed-based chemotherapy (Type: EXPERIMENTAL): Raltitrexed plus Oxaliplatin/Raltitrexed plus Irinotecan
- 5-fluorouracil-based chemotherapy (Type: ACTIVE_COMPARATOR): 5-fluorouracil plus Oxaliplatin/5-fluorouracil plus Irinotecan

Based on this trial design, predict the completion outcome and termination type (if applicable).